Big concerns are erupting over a memo from the United States’ top vaccines official, which claims to overhaul how vaccine regulation should work after alleging that at least 10 children died following Covid vaccination. The memo, sent to staff in a long, argumentative format, provides few specifics or evidence for that claim and offers little detail about the proposed regulatory changes.
Experts worry that these top-down changes—made without outside input or public data—could hasten the removal of vaccines like the flu shot and erode public trust. If fewer vaccines are available, illness from vaccine-preventable diseases could rise, according to Dan Jernigan, a former director at the CDC’s infectious disease center.
The 10 reported child deaths relate to ages seven through 16 and span 2021 to 2024. They appear in VAERS, a user-submitted database for vaccine side effects. Vinay Prasad, who leads the FDA’s Center for Biologics Evaluation and Research (CBER), and serves as chief medical and scientific officer at the FDA, shared this detail but did not provide additional information about the cases (such as the specific conditions involved, how deaths were linked to vaccination, or why earlier investigations found no link while later ones did).
Prasad asserted in the memo that, for the first time, the FDA would acknowledge that Covid vaccines have killed American children and questioned whether they saved more healthy kids than they harmed. Paul Offit, an infectious disease expert at the Children’s Hospital of Philadelphia, argued that such a sensational claim requires solid evidence, which he said the memo lacks.
The Covid vaccines have been broadly distributed and are considered safe and effective by the broader medical community. The memo’s approach and its claims diverge markedly from the FDA’s traditional procedures. Former CDC veteran Jernigan described the situation as unprecedented, noting that it’s unusual for an FDA vaccine chief to disseminate such information via email to all staff without convening the VRBPAC or presenting data publicly, as is customary.
The memo does not specify causes of death, but Prasad highlights myocarditis—a rare heart inflammation observed after vaccination—as a potential factor. He notes that myocarditis is far more common and severe when caused by a Covid infection, whereas vaccination lowers the risk of infection and severe illness. If myocarditis were responsible for any deaths, an autopsy would typically reveal such damage; autopsies are standard in unexpected pediatric deaths, according to Offit. Proving a vaccine-induced myocarditis link would also require ruling out infections or other causes.
Tracy Beth Høeg, a sports medicine physician and FDA senior advisor, led an investigation over the summer, per Prasad. The memo also credits FDA Commissioner Marty Makary for identifying the cases and promises regulatory changes designed to prevent similar investigations in the future. Prasad claimed the deaths are likely underestimated and that the true figure is higher, though no supporting evidence was provided.
Requests for data and details about attributing the deaths to vaccination or how vaccine-regulation changes would be implemented were not answered by press time.
The Apollo-like achievement of developing Covid vaccines during the early Trump administration is acknowledged by Offit as a major scientific milestone. Yet the notion that the FDA’s top regulator would claim vaccines killed at least 10 children raises questions about credibility and process.
White House commentary on these claims has been unavailable at press time.
Historically, communications around adverse events intensified during Covid vaccine rollout. The CDC pushed reporting through campaigns and systems like V-safe, which used texts to prompt symptom reporting to VAERS. The VSD database, covering roughly 10% of the U.S. population and about half a million children, is described as a robust resource for confirming signals seen in VAERS. This framework helped detect myocarditis after vaccination and rare clotting events linked to certain vaccines.
Prasad’s memo also touches on broader vaccine strategies. He suggests the FDA may rethink giving multiple vaccines at once, though the memo lacks concrete harm evidence. Some experts argue that simultaneous vaccination has a long history of safety, and changing this without evidence could hinder vaccine approval.
For measles, mumps, and rubella (MMR) vaccines, Prasad notes benefits to society when coverage is high, but it remains unclear how lower uptake would affect these benefits.
Under the new framework, the FDA would require randomized trials demonstrating real-world clinical benefits (reduced illness) rather than primarily immune response data for most new vaccines. The plan also proposes revising the annual flu vaccine process by moving away from surrogate immune measures toward more direct outcome data. Critics note that flu-season timing makes timely new trials impractical, potentially delaying updates.
Most experts agree that delaying updates to influenza and Covid vaccines would be risky, especially given a difficult flu season and ongoing viral threats. Reducing vaccine access could result in preventable deaths, a point underscored by concerns over current pediatric hospitalization and mortality from the virus.
This situation highlights confusion around evidence and trust in health agencies. The public and medical professionals are finding it harder to discern which recommendations to follow and whom to trust, creating a fragile landscape for vaccine guidance.
Would you side with faster, centralized regulatory changes that bypass broader consultation, or with a more transparent, data-driven approach that prioritizes proven safety and public confidence? How should regulators balance the urgency of updating vaccines with the need for robust evidence and public trust?
